Horizon Therapeutics (HZNP)
Horizon is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. The Company pipeline is purposeful: it applyie scientific expertise and courages to bring clinically meaningful therapies to patients. The Company believes science and compassion must work together to transform lives.

Company profile
Ticker
HZNP
Exchange
Website
CEO
Timothy P. Walbert
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Horizon Pharma plc, HORIZON PHARMA, INC.
SEC CIK
Corporate docs
Subsidiaries
Horizon Medicines LLC • Horizon Ophthalmology, Inc • Horizon Orphan Holdings LLC • Horizon Orphan LLC • Horizon Properties Holding LLC • Horizon Therapeutics Brasil Ltda • Horizon Therapeutics Capital Limited • Horizon Therapeutics Finance Limited • Horizon Therapeutics Finance • Horizon Therapeutics France SAS ...
IRS number
272179987
HZNP stock data
News

Horizon Therapeutics Begins Patient Enrolment in Phase 2 trial of Daxdilimab (HZN-7734) for Alopecia Areata
17 May 22
Horizon Therapeutics Announces First Patient Enrolled In Phase 2 Trial Evaluating Daxdilimab (HZN-7734) For The Treatment Of Alopecia Areata
17 May 22
Morgan Stanley Maintains Overweight on Horizon Therapeutics, Lowers Price Target to $135
5 May 22
Horizon Therapeutics: Q1 Earnings Insights
4 May 22
Horizon Therapeutics Q1 Adj. EPS $1.34 Beats $1.20 Estimate, Sales $885.20M Beat $874.41M Estimate; Reaffirms FY22 Guidance
4 May 22
Press releases
Horizon Therapeutics plc Announces Dara Mann as a Healthcare Businesswomen's Association 2022 Rising Star
11 May 22
Horizon Therapeutics plc Launches Letter-Writing Campaign to Empower Those Living with Thyroid Eye Disease (TED) to Confront the Condition Head On
11 May 22
Horizon Therapeutics and Chicago Sky Announce Multi-Year Partnership
9 May 22
Horizon Therapeutics plc Reports First-Quarter 2022 Financial Results
4 May 22
Topline Data for Dazodalibep (HZN-4920) Meets Primary Endpoint in Rheumatoid Arthritis
3 May 22
Analyst ratings and price targets
Current price
Average target
$137.50
Low target
$135.00
High target
$140.00
Morgan Stanley
Maintains
$135.00
Oppenheimer
Initiated
$140.00
Investment data
Securities sold
Number of investors
Calendar
4 May 22
17 May 22
31 Dec 22
Financial summary
Quarter (USD) | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
11 May 22 | Timothy P Walbert | Ordinary Shares | Sell | Dispose S | No | Yes | 90 | 17,600 | 1.58M | 460,549 |
11 May 22 | Timothy P Walbert | Ordinary Shares | Option exercise | Acquire M | No | No | 22.14 | 17,600 | 389.66K | 478,149 |
11 May 22 | Timothy P Walbert | Stock Option Ordinary Shares | Option exercise | Dispose M | No | No | 22.14 | 17,600 | 389.66K | 792,565 |
6 May 22 | Timothy P Walbert | Ordinary Shares | Sell | Dispose S | No | Yes | 91.11 | 5,000 | 455.55K | 460,549 |
6 May 22 | Timothy P Walbert | Ordinary Shares | Sell | Dispose S | No | Yes | 90.33 | 2,400 | 216.79K | 465,549 |
6 May 22 | Timothy P Walbert | Ordinary Shares | Option exercise | Acquire M | No | No | 22.14 | 7,400 | 163.84K | 467,949 |
6 May 22 | Timothy P Walbert | Stock Option Ordinary Shares | Option exercise | Dispose M | No | No | 22.14 | 7,400 | 163.84K | 810,165 |
2 May 22 | Timothy P Walbert | Ordinary Shares | Sell | Dispose S | No | Yes | 97.43 | 3,450 | 336.13K | 460,549 |
2 May 22 | Timothy P Walbert | Ordinary Shares | Sell | Dispose S | No | Yes | 96.62 | 7,608 | 735.08K | 463,999 |
2 May 22 | Timothy P Walbert | Ordinary Shares | Sell | Dispose S | No | Yes | 95.38 | 13,942 | 1.33M | 471,607 |
Institutional ownership, Q4 2021
87.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 588 |
Opened positions | 95 |
Closed positions | 57 |
Increased positions | 220 |
Reduced positions | 204 |
13F shares | Current |
---|---|
Total value | 21.75B |
Total shares | 201.87M |
Total puts | 750.8K |
Total calls | 981.39K |
Total put/call ratio | 0.8 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 20.14M | $2.17B |
FMR | 15.87M | $1.71B |
BLK Blackrock | 13.01M | $1.4B |
Avoro Capital Advisors | 9.3M | $1B |
JHG Janus Henderson | 7.05M | $759.95M |
Nuveen Asset Management | 7.05M | $759.22M |
JPM JPMorgan Chase & Co. | 6.08M | $655.28M |
Paulson & Co. | 6M | $646.56M |
STT State Street | 5.47M | $589.91M |
BK Bank Of New York Mellon | 3.65M | $392.86M |
Financial report summary
?Competition
Aradigm • Cymabay Therapeutics • Acer Therapeutics • United Therapeutics • iBio • Tonix Pharmaceuticals Holding • Chemomab Therapeutics • Viridian Therapeutics • Allena Pharmaceuticals • Aeglea BioTherapeuticsManagement Discussion
- Developed technology and other intangible assets, net. Developed technology and other intangible assets, net, decreased $88.1 million, from $2,960.1 million as of December 31, 2021 to $2,872.0 million as of March 31, 2022, primarily related to amortization of developed technology during the three months ended March 31, 2022.
- In-process research and development. In April 2022, the European Commission granted marketing authorization for UPLIZNA for the treatment of adult patients with NMOSD in the European Union. As a result, we expect to reclass $70.0 million of in-process research and development to developed technology in the second quarter of 2022.
- Goodwill. At September 30, 2021, we determined that an interim impairment analysis of the inflammation reporting unit’s $56.2 million goodwill balance was warranted. The fair value of the inflammation reporting unit exceeded its carrying value by more than 30% as of September 30, 2021, the interim testing date, resulting in no impairment. In order to evaluate the sensitivity of the fair value calculations on the goodwill impairment test, we applied a hypothetical 10 percent decrease to the fair values of the reporting unit. A 10% decrease in fair value would reduce the excess of the reporting unit’s fair value over its carrying value to approximately 19%.
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. senior Avg
|
New words:
adult, Alpine, Authorisation, batch, begun, biopharmaceutical, Brazil, CDPA, Centralised, cessation, Commerce, CPA, cultivate, DISSOLVE, Division, dual, earnout, entrant, Fisher, FL, Florida, forfeited, geopolitical, ImmTOR, immune, immunoglobulin, IND, invasion, jointly, lesser, meantime, monotherapy, Notably, notional, omicron, partnership, passage, Patheon, pediatric, pegadricase, pertaining, phenylbutyrate, philosophy, platform, Pollution, qualitative, readily, reexport, remeasured, remeasurement, retired, retirement, Russia, seropositive, settled, shortage, subside, symptomatic, Thermo, UCPA, Ukraine, unique, unrealized, uricase, Utah, variant, waned, warranted, Watson
Removed:
abandoned, accumulation, achieved, adjust, Alkem, AMT, anesthesiologist, anniversary, antagonist, appeal, arrangement, ASU, ataxia, Attorney, Biomedical, Breakthrough, Carbaglu, carried, ceased, Center, Certification, CID, Circuit, Clinigen, close, closely, Collaborative, communication, compliant, component, compounded, conformity, conventional, cooperating, corneal, crystal, Curzion, CystaranTM, cystine, declined, deductibility, Delaware, delivery, derive, detail, detain, discover, dissolution, distancing, dose, draft, driver, Duchy, earned, efficient, elimination, employer, endocrinology, ENHANZE, entry, Escalation, exercisable, expensed, explanation, extinguished, extinguishment, failed, Fast, faster, Friedreich, Gaithersburg, Grand, granting, Halozyme, harder, harmonization, harmonized, Hatch, HemoShear, IMUKIN, incomplete, insight, interactive, interferon, introduce, investigation, Japanese, lab, Los, Lundquist, Lupin, Luxembourg, lysophosphatidic, majeure, Mayo, met, metabolite, mid, NBI, negotiate, newly, offshore, oncology, ophthalmic, opposed, Ops, optimal, optimize, Orange, Parliament, path, practitioner, privately, progressive, prolonged, promise, qualification, recall, receptor, recoup, red, reimbursable, removal, renamed, repatriated, repealing, repositioned, requesting, requisite, restarting, restructured, revise, revoke, SC, seize, selective, serum, shipping, shortening, shortly, Simplification, Southern, sponsor, strong, subpoena, successive, suspend, taxpayer, Tech, thirty, tied, timeline, Tolerability, Topic, track, transitioned, UCSD, unchanged, uncured, uric, Waxman
Financial reports
Current reports
8-K
Horizon Therapeutics plc Reports First-Quarter 2022 Financial Results
4 May 22
8-K
Departure of Directors or Certain Officers
29 Apr 22
8-K
Horizon Therapeutics plc Reports Fourth-Quarter 2021 and Full-Year 2021
1 Mar 22
8-K
Results of Operations and Financial Condition
10 Jan 22
8-K
Regulation FD Disclosure
16 Dec 21
8-K
Results of Operations and Financial Condition
3 Nov 21
8-K
Other Events
29 Sep 21
8-K
Horizon Therapeutics plc Reports Record Second-Quarter 2021 Financial Results; Increasing Full-Year 2021 Net Sales and Adjusted EBITDA Guidance
4 Aug 21
8-K
Horizon Therapeutics plc Reports First-Quarter 2021 Financial Results; Updating
5 May 21
8-K
Departure of Directors or Certain Officers
30 Apr 21
Registration and prospectus
S-8
Registration of securities for employees
30 Apr 21
S-8
Registration of securities for employees
30 Apr 21
SC TO-T/A
Third party tender offer statement (amended)
15 Mar 21
SC TO-T/A
Third party tender offer statement (amended)
12 Mar 21
SC TO-T/A
Third party tender offer statement (amended)
3 Mar 21
SC TO-T/A
Third party tender offer statement (amended)
26 Feb 21
SC TO-T/A
Third party tender offer statement (amended)
24 Feb 21
SC TO-T
Third party tender offer statement
12 Feb 21
SC TO-C
Information about tender offer
4 Feb 21
SC TO-C
Information about tender offer
1 Feb 21
Proxies
Other
UPLOAD
Letter from SEC
8 Dec 21
CORRESP
Correspondence with SEC
21 Nov 21
CORRESP
Correspondence with SEC
24 Oct 21
UPLOAD
Letter from SEC
12 Oct 21
CORRESP
Correspondence with SEC
6 Oct 21
CT ORDER
Confidential treatment order
22 Sep 21
CORRESP
Correspondence with SEC
26 Aug 21
UPLOAD
Letter from SEC
22 Aug 21
CT ORDER
Confidential treatment order
4 Aug 21
CT ORDER
Confidential treatment order
22 Jun 21
Ownership
3
Horizon Therapeutics Public / Aaron Cox ownership change
16 May 22
4
Horizon Therapeutics Public / Timothy P Walbert ownership change
13 May 22
4
Horizon Therapeutics Public / Timothy P Walbert ownership change
10 May 22
4
Horizon Therapeutics Public / Timothy P Walbert ownership change
4 May 22
4
Horizon Therapeutics Public / Susan Mahony ownership change
2 May 22
4
Horizon Therapeutics Public / Thomas Watkins ownership change
2 May 22
4
Horizon Therapeutics Public / Pascale Witz ownership change
2 May 22
4
Horizon Therapeutics Public / MICHAEL G GREY ownership change
2 May 22
4
Horizon Therapeutics Public / William F Daniel ownership change
2 May 22
4
Horizon Therapeutics Public / Jeff Himawan ownership change
2 May 22
Patents
Utility
Topical Use of Levofloxacin for Reducing Lung Inflammation
17 Mar 22
The present invention relates to methods and compositions for the treatment of pulmonary inflammation.
Utility
Ado-resistant Cysteamine Analogs and Uses Thereof
27 Jan 22
The present disclosure is directed to methods for treating diseases for which cysteamine is indicated and compounds useful in such methods.
Utility
Methods for the Treatment of Thyroid Eye Disease
16 Sep 21
The invention provides a method of treating or reducing the severity of thyroid-associated ophthalmopathy (TAO), also known as thyroid eye disease (TED) or Graves' ophthalmopathy or orbitopathy (GO), as well as antibodies, or antigen binding fragments thereof, and pharmaceutical compositions comprising them, useful in the methods.
Utility
Methods for the Treatment of Scleroderma and Related Conditions
19 Aug 21
Provided herein are antibodies against insulin-like growth factor 1 receptor (IGF-1R) and their use in methods of treatment of, and achievement of clinical outcomes in, scleroderma and forms thereof, including diffuse cutaneous systemic sclerosis.
Utility
Methods for the Treatment of Thyroid Eye Disease
19 Aug 21
Provided herein are methods of treating or reducing the severity of thyroid eye disease (TED), also known as thyroid-associated ophthalmopathy (TAO), or Graves' ophthalmopathy or orbitopathy (GO), as well as antibodies, or antigen binding fragments thereof, and pharmaceutical compositions comprising them, useful in the methods.
Transcripts
2022 Q1
Earnings call transcript
4 May 22
2021 Q4
Earnings call transcript
1 Mar 22
2021 Q3
Earnings call transcript
3 Nov 21
2021 Q2
Earnings call transcript
4 Aug 21
2021 Q1
Earnings call transcript
5 May 21
2020 Q4
Earnings call transcript
24 Feb 21
2020 Q3
Earnings call transcript
2 Nov 20
2020 Q3
Earnings call transcript
2 Nov 20
2020 Q3
Earnings call transcript
2 Nov 20
2020 Q2
Earnings call transcript
5 Aug 20
Reddit threads
What Are Your Favorite *Oversold* Value Stocks Of 2022 So Far?
12 May 22
(5/4) Wednesday's Pre-Market Stock Movers & News
4 May 22
(5/4) Wednesday's Pre-Market Stock Movers & News
4 May 22
Daily Discussion Thread - May 4th, 2022
4 May 22
Daily Discussion Thread - May 3rd, 2022
3 May 22
Daily Discussion Thread - May 2nd, 2022
2 May 22
Daily Discussion Thread - March 1st, 2022
1 Mar 22
Daily Discussion Thread - February 28th, 2022
28 Feb 22
Searing Criticism on ARK's Genomic Bets in FT. What do you think?
19 Feb 22
My biggest bags
2 Feb 22